The DEA Can Ban 7-OH Starting Tomorrow. It Tried This Once Before, and Lost.

Somewhere in Whatcom County, Washington, a man in his mid-30s named Dan gets up in the morning and decides how much 7-OH he needs to get through the day without the sweats starting. He’s been doing this math for months, buying the concentrated kratom extract from a gas station or a smoke shop the way other people buy coffee, because it is legal, it is nearby, and it keeps him from feeling like his skin is trying to leave his body. Starting any day now, the federal government can make that math a felony.

The Drug Enforcement Administration filed notice on July 1 that it intends to temporarily place 7-hydroxymitragynine — 7-OH for short — into Schedule I, the same legal category as heroin. The earliest the order can take effect is August 5, 2026. Tomorrow. When it does, it will not touch raw kratom leaf or powder, which stays legal below a specified concentration. It will hit the concentrated pills, gummies, and shots that people like Dan have been using, often because nothing else was available to them, cheaper, or as fast.

The DEA is about to make it a crime to possess the thing that’s keeping some people off fentanyl, and it has not funded a single new bed, prescriber, or dollar of treatment to replace it.

Here is what 7-OH actually is, in plain terms: kratom leaf naturally contains a tiny amount of a compound called 7-hydroxymitragynine, which acts on the same opioid receptors in your brain that morphine and fentanyl do. On its own, in the leaf, the concentration is low enough that most people who chew kratom or brew it as tea feel something closer to a stimulant buzz. What’s sold in gas stations now isn’t that. Manufacturers extract and concentrate 7-OH until it is, by the DEA’s own estimate, roughly 13 times more potent than morphine — a full-strength opioid sold next to the beef jerky, with no age check tied to its actual pharmacology and no dosing guidance beyond what’s printed on a gummy label.

We have watched this exact fight before

This is not the DEA’s first attempt. On August 30, 2016, the agency announced it would use its emergency scheduling power to place kratom’s two main alkaloids — mitragynine and 7-hydroxymitragynine — into Schedule I within 30 days, no public comment required. What happened next is the part the current notice doesn’t mention: the DEA received more than 2,000 calls, mostly in opposition, watched advocacy groups organize demonstrations and petitions, and faced a bipartisan letter from members of Congress demanding it slow down. Kratom users argued the plant was helping them manage chronic pain and taper off prescription opioids, and there was no epidemiological evidence of the mass harm the emergency-scheduling standard is supposed to require. On October 12, 2016, the DEA withdrew the notice entirely and opened a formal comment period instead — an almost unheard-of reversal for an agency that rarely walks back a scheduling action once announced. Forbes called it a rare retreat at the time, and CNN framed it as a reprieve that kratom advocates had fought hard to win.

Nine years later, the agency is trying a narrower version of the same move — targeting the concentrated derivative instead of the whole plant, which makes the legal footing sturdier and the political backlash harder to mobilize around. But the underlying tension hasn’t changed: a federal agency moving to criminalize a substance faster than the healthcare system can build an alternative for the people already using it.

The clinical picture doesn’t match a niche problem

Averil True, a physician assistant at Ideal Option in Whatcom County, is now seeing four new kratom or 7-OH addiction cases every week — at one clinic, in one county. Some of her patients are as young as 15. In the emergency department at PeaceHealth St. Joseph, Dr. Arielle Filiberti describes patients coming in “being treated like [a] person who’s addicted to fentanyl,” she told Cascadia Daily News — the same withdrawal timeline, the same physiological terror, the same need for medical support to get through it safely. One patient’s case escalated far enough to need a continuous naloxone infusion in intensive care, on the edge of requiring a ventilator, from a product legally purchased at a gas station.

What makes the caseload harder to write off as a fringe issue is who’s showing up. Dr. Adam Kartman at Cascade Medical Advantage told the paper his new 7-OH patients are typically employed, “largely affluent,” and not using other drugs — not the profile most policymakers picture when they imagine an opioid use disorder starting. Some users are spending up to $250 a day to keep withdrawal at bay, a habit with the price tag of a serious dependency and the retail footprint of a snack.

What makes the caseload harder to write off as a fringe issue is who’s showing up.

Whatcom County isn’t waiting on Washington, D.C. Spokane and Spokane Valley have already banned kratom sales outright in 2026, and Mount Vernon’s city council directed its attorney on July 29 to draft a model ordinance. State Representative Joe Timmons told the paper he expects kratom legislation back on the docket next session after three separate bills failed in Olympia. Local officials are moving in the direction of restriction with or without the DEA — which is worth sitting with, because it means the federal scheduling fight is happening downstream of a problem communities are already trying to solve on their own.

What the scheduling order doesn’t fix

Here’s the part that should worry you even if you think 7-OH deserves to be restricted: banning the concentrated product doesn’t do anything about the reason people are buying it. Kratom and 7-OH became a $15,000-a-year habit for some chronic pain patients, and a daily ritual for people like Dan, largely because the alternative — a buprenorphine prescriber with an open slot, a detox bed, a doctor willing to treat withdrawal as a medical event instead of a moral one — wasn’t there when they needed it, or wasn’t affordable, or came with a six-week waitlist. If you have ever tried to time a taper around a clinic’s next available appointment, you already know that “make the workaround illegal” isn’t treatment. It’s a bet placed with someone else’s withdrawal.

The DEA’s own justification for this action, as HHS confirmed in the agency’s release, is that 7-OH has “no accepted medical use and a high potential for abuse” — the standard Schedule I finding. Notably absent from the DEA’s own announcement is any of the quantitative data you’d expect to justify an emergency order: no national overdose count, no hospitalization tally, no poison-control trendline. The agency’s public case rests on describing the products as posing effects that are “highly unpredictable,” not on a body count it’s willing to publish. That’s not necessarily wrong — concentrated 7-OH probably does deserve tighter control than an unregulated gas-station product currently gets. But an emergency order built on a description instead of a dataset is exactly the kind of move that triggered the 2016 backlash, and there’s no visible plan this time for what happens to the people already dependent on it once the shelves clear.

That gap matters clinically, not just politically. Every prescriber interviewed in the Whatcom County reporting described 7-OH withdrawal as functionally identical to opioid withdrawal — because pharmacologically, it is one. Cutting off legal, if unregulated, access to an opioid-receptor agonist without expanding access to buprenorphine, methadone, or supervised taper support doesn’t make the underlying physical dependence disappear. It removes the version of the substance that was, at minimum, consistently dosed and sold in daylight, and leaves people to find something else — which, in a fentanyl-saturated drug supply, is a considerably worse bet.

Buprenorphine prescribing rules loosened years ago — most physicians can now write the script without the old federal waiver — but loosening a rule on paper is not the same as a patient getting an appointment. A same-week induction slot still depends on a local clinic having capacity, on insurance actually covering it, on someone answering the phone. Scheduling 7-OH does nothing to shorten that wait. It just removes the thing people were using to survive it, on the same week the wait is still six weeks long in most of the country outside a handful of well-resourced metro areas.

There is one thing worth holding onto if you or someone you know is in this exact bind tonight: naloxone still works on a 7-OH overdose the same way it works on a fentanyl one, because it’s still an opioid on the receptor level — that’s precisely why the ICU patient in Whatcom County survived on a continuous Narcan infusion. Whatever Congress and the DEA settle on by August 5, that fact doesn’t change. Carrying naloxone and knowing how to use it remains real, funded, and legal, regardless of which schedule 7-OH lands in next week.

Carrying naloxone and knowing how to use it remains real, funded, and legal, regardless of which schedule 7-OH lands in next week.

The 2016 fight ended because enough people said, loudly and specifically, that a scheduling decision built on description instead of data was going to hurt real patients — and the DEA, uncharacteristically, listened. Nine years later, Dan is still doing the morning math on how much 7-OH gets him through the day, the DEA is still moving faster than the treatment system it would displace, and the only thing anyone can say for certain is that whichever way this order lands, the withdrawal doesn’t check the federal calendar. It’s arriving either way. The only open question is whether anyone will be there to treat it as medicine instead of a crime.

For the harm reduction response this keeps colliding with — test strips, naloxone access, and now scheduling fights that outrun treatment capacity — see our earlier coverage of the DEA’s 7-OH comment deadline and the kratom substance pillar for the full policy timeline.